• COMBIPRASAL is indicated for the management of bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD) who require regular treatment with both ipratropium bromide and salbutamol.
• Cost effective than generic combination therapy with improved patient compliance
• Method of administration - Inhalation use only.
• Bioequivalent to the originator brand

• Available Strengths :0.5 mg / 2.5 mg Nebuliser Solution
• Pack Size :60 x 2.5ml Vials
• Dose :One single-dose container three or four times daily.
• POM

Ipratropium Bromide + Salbutamol cost effectiveness with COMBIPRASAL Nebuliser Solution